lncTAC is a biotech company and the first in China dedicated to developing lncRNA-based therapeutics and pioneering extrahepatic drug delivery utilizing lncRNA and other natural molecules. We are actively seeking out-licensing/Co-development partners for ex-China for our technology platforms and early-stage assets.

Our lead asset, targeting dermatological disease, is scheduled to enter clinical trials in Q1 2026. Our therapeutic areas cover oncology, dermatology, CNS, respiratory and metabolic diseases, our extrahepatic delivery platform has been preliminarily validated in tissues including skin, tumors, brain, lung, adipose, and muscle.